TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06747858: Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

Sponsor: Arcturus Therapeutics, Inc. · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 33 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$2,523,500

Rescue Site Savings

+$1,648,000

Unlock Full NCT06747858 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06747858 Rescue Dossier →